Patents by Inventor Philippe Erbs

Philippe Erbs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190330655
    Abstract: The present invention relates to an oncolytic virus encoding a cytidine deaminase (CDAse) polypeptide, a composition comprising it, as well as their use for prophylactic or therapeutic purposes, and more particularly for the treatment of cancer. The present invention also provides a method for treating a disease or a pathologic condition comprising the administration of such an oncolytic virus or composition thereof and a process for preparing such an oncolytic virus.
    Type: Application
    Filed: December 21, 2017
    Publication date: October 31, 2019
    Applicant: TRANSGENE SA
    Inventors: Philippe ERBS, Johann FOLOPPE
  • Patent number: 9884080
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 6, 2018
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9687515
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 27, 2017
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9180150
    Abstract: A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: November 10, 2015
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9024003
    Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: May 5, 2015
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
  • Publication number: 20150017126
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Application
    Filed: April 10, 2014
    Publication date: January 15, 2015
    Applicant: Transgene S.A.
    Inventors: Philippe ERBS, Johann Foloppe
  • Patent number: 8778328
    Abstract: A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: July 15, 2014
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Publication number: 20130287737
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Application
    Filed: February 27, 2013
    Publication date: October 31, 2013
    Applicant: TRANSGENE S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Publication number: 20130244246
    Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Application
    Filed: December 21, 2012
    Publication date: September 19, 2013
    Applicant: TRANSGENE S.A.`
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Patent number: 8513018
    Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: August 20, 2013
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Patent number: 8470591
    Abstract: The present invention relates to a kit of parts comprising a nucleic acid sequence encoding a permease and a drug comprising one nucleobase moiety or a precursor thereof. The present invention further relates to a kit of parts comprising a precursor of a drug comprising a gene coding a permease and a nucleic acid sequence comprising a suicide gene. The present invention also relates to a vector comprising a gene coding a permease and a suicide gene.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: June 25, 2013
    Assignee: Transgene S.A.
    Inventor: Philippe Erbs
  • Publication number: 20130095557
    Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Application
    Filed: June 29, 2011
    Publication date: April 18, 2013
    Applicant: TRANSGENE S.A.
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Publication number: 20130039891
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Application
    Filed: September 15, 2012
    Publication date: February 14, 2013
    Applicant: TRANSGENE S.A.
    Inventors: Philippe ERBS, Johann Foloppe
  • Patent number: 8361788
    Abstract: Immortalized avian cell lines containing E1A nucleic acid sequences are useful for the production of viruses and are particularly useful for the production of recombinant viral vectors which can be employed for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: January 29, 2013
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Patent number: 8357531
    Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 22, 2013
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Publication number: 20120238000
    Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Application
    Filed: May 29, 2012
    Publication date: September 20, 2012
    Applicant: Transgene S.A.
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Patent number: 8257692
    Abstract: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: September 4, 2012
    Assignee: Transgene, S.A.
    Inventor: Philippe Erbs
  • Patent number: 8226954
    Abstract: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: July 24, 2012
    Assignee: Transgene S.A.
    Inventor: Philippe Erbs
  • Patent number: 8211421
    Abstract: The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them. The invention further concerns their therapeutic use and a treatment method using them. The invention is particularly useful in the context of therapy by suicide genes, in particular, for treating proliferative and infectious diseases.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 3, 2012
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Richard Jund
  • Publication number: 20110059049
    Abstract: A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Application
    Filed: November 17, 2008
    Publication date: March 10, 2011
    Inventors: Philippe Erbs, Johann Foloppe